ARCHIVES

Advisors Voted For Provenge Approval Despite Fundamental Flaws In Trials.

This article is from The Cancer Letter archive.

Vol. 33 No. 14 | April 13, 2007

Download PDF Visit The Full Archive

Related Articles

The Antineoplaston Anomaly: How A Drug Was Used For Decades In Thousands Of Patients, With No Safety, Efficacy Data

September 25, 1998

In Brief: FASEB Report On Diet and Cancer Mortality Available; Don Poppke AO of Nursing Center

March 6, 1987

Cooney to Oversee University of Michigan Clinical Operations

February 7, 2013

$1.5 Million In Direct Costs Is Proposed Core Grant Requirement

July 12, 1991

NCI CTEP-Approved Trials For the Month of September

September 26, 2014

Bypass Budget Will Call For 15-percent Increase

February 18, 2011